A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05028348
• Other study ID #: EMN29
• Status: Recruiting
• Phase: Phase 3
• Start date: April 19, 2022
• Est. completion date: March 2029

Study information

• Verified date: February 2023
• Source: European Myeloma Network
• Contact: European Myeloma Network (EMN)
• Phone: +31 107033123
• Email: chiara.pautasso[@]emnitaly.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 222
• Est. completion date: March 2029
• Est. primary completion date: March 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Relapsed or refractory MM with measurable disease per IMWG guidelines as defined by at least 1 of the following:

1. Serum M-protein =0.5 g/dL (=5 g/L) by serum protein electrophoresis (SPEP) or, for immunoglobulin (Ig) A or D myeloma, by quantitative serum IgA or IgD levels = 0.5 g/dL.

2. Urinary M-protein excretion =200 mg/24 hours

3. Serum free light chain (FLC) =100 mg/L, provided that the FLC ratio is abnormal (normal FLC ratio: 0.26 to 1.65)

2. Received at least 1 and no more than 4 prior anti-MM lines of therapy. Induction therapy followed by stem cell transplant and consolidation/maintenance therapy will be considered as 1 line of therapy.

3. Prior therapy that includes = consecutive cycles of lenalidomide and a proteasome inhibitor given alone or in combination

4. Prior therapy with an anti-CD3 mAb as part of their immedicate last treatment prior to study entry (Before protocol version2.0, patient with any prior therapy with an anti-CD3 mAb were eligible for the study).

5. Eastern Cooperative Oncology Group (ECOG) performance status of =2.

6. Resolution of any clinically significant non-hematological toxicities (if any) from previous treatments to Grade =1 by Cycle 1 Day 1 (C1D1). Patients with Grade 2 non-hematological toxicities may be included.

7. Adequate hepatic function within 28 days prior to C1D1:

1. Total bilirubin <2 × upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of <3 × ULN)

2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2.5 × ULN

8. Adequate renal function within 28 days prior to C1D1 (estimated creatinine clearance [CrCl] of =15 mL/min (not requiring dialysis), calculated using the formula of Cockcroft and Gault or measured by 24-hour urine collection).

9. Adequate hematopoietic function within 7 days prior to C1D1 defined as absolute neutrophil count =1.5 x 109/L , hemoglobin =8.5 g/dL, and platelet count =100 x 109/L (patients for whom <50% of bone marrow nucleated cells are plasma cells) or =75 x 109/L (patients for whom =50% of bone marrow nucleated cells are plasma cells).

1. Patients receiving hematopoietic growth factor support, including erythropoietin, darbepoetin, granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), and platelet stimulators (e.g., eltrombopag, romiplostim, or interleukin-11) must have a 2-week interval between growth factor support and the Screening assessments, but they may receive growth factor support during the study.

2. Patients must have:

• At least a 2-week interval from the last red blood cell (RBC) transfusion prior to the Screening hemoglobin assessment, and

• At least a 1-week interval from the last platelet transfusion prior to the Screening platelet assessment.

However, patients may receive RBC and/or platelet transfusions as clinically indicated per institutional guidelines during the study.

10. Patients with active hepatitis B virus (HBV) are eligible if antiviral therapy for hepatitis B has been given for >8 weeks and viral load is <100 IU/mL. Patients with evidence of non-active HBV should be discussed with the Medical Monitor and should be monitored or receive prophylaxis at the discretion of the Investigator and study site institutional guidelines

11. Patients with a history of hepatitis C virus (HCV) are eligible if they have received adequate curative anti-HCV treatment and HCV viral load is below the limit of quantification.

12. Patients with a history of human immunodeficiency virus (HIV) are eligible if they have CD4+ T cell counts =350 cells/µL, negative viral load, and no history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections in the last year and should be on established antiretroviral therapy (ART) for at least 4 weeks.

13. Female patients of childbearing potential must have a negative serum pregnancy test within 10 to 14 days and a second test within 24 hours prior to the first dose of study treatment. Female patients of childbearing potential and fertile male patients who are sexually active must use highly effective methods of contraception throughout the study and for 3 months following the last dose of study treatment.

14. Age =18 years at the time of signing informed consent.

15. Written informed consent signed in accordance with federal, local, and institutional guidelines.

16. Patients must be able and willing to take enteric-coated aspirin according to clinical practice, or if history of prior thrombotic disease, must be fully anticoagulated with warfarin (international normalized ratio [INR] 2-3) or be treated with full-dose, low molecular weight heparin, as if to treat deep venous thrombosis (DVT)/pulmonary embolism (PE) at the Investigator's discretion. For patient on warfarin, INR should be repeated as clinically indicated. Use of alternative anticoagulants, such as direct oral anticoagulants, may be considered per Investigator discretion.

Exclusion Criteria:

1. Smoldering MM.

2. Plasma cell leukemia.

3. Documented active systemic amyloid light chain amyloidosis.

4. Any history of central nervous system MM.

5. Prior treatment with:

1. A selective inhibitor of nuclear export (SINE) compound, including selinexor

2. Pomalidomide and/or elotuzumab.

6. Any concurrent medical condition or disease that is likely to interfere with study procedures.

7. Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to C1D1. Patients on prophylactic antibiotics or with a controlled infection within 1 week prior to C1D1 are acceptable.

8. Known intolerance, hypersensitivity, or contraindication to any of the study treatments.

9. Radiation, chemotherapy, or immunotherapy or any other anticancer therapy including investigational therapies and high dose dexamethasone (i.e., 40 mg daily for 4 days per week) =2 weeks prior to C1D1. Patients on long-term glucocorticoids during Screening do not require a washout period but must be able to tolerate the specified dexamethasone dose in this study.

10. Prior autologous stem cell transplantation <60 days or allogeneic stem cell transplantation <4 months prior to C1D1.

11. Major surgery within 4 weeks prior to C1D1.

12. Active graft versus host disease after allogeneic stem cell transplantation.

13. Pregnant or breastfeeding females.

14. In the opinion of the Investigator, patients who are below their ideal body weight and would be unduly impacted by changes in their weight.

15. Clinically significant cardiac disease, including:

1. Myocardial infarction within 6 months before C1D1, or unstable or uncontrolled disease/condition related to or affecting cardiac function (e.g., unstable angina, congestive heart failure, New York Heart Association Class III-IV).

2. Uncontrolled cardiac arrhythmia (CTCAE v. 5.0 Grade 2 or higher) or clinically significant electrocardiogram (ECG) abnormalities.

3. Screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) >470 msec.

16. Any active gastrointestinal dysfunction interfering with the patient's ability to swallow tablets, or any active gastrointestinal dysfunction that could interfere with absorption of study treatment.

17. Any active, serious psychiatric, medical, or other conditions/situations that, in the opinion of the Investigator, could interfere with treatment, compliance, or the ability to give informed consent.

18. Contraindication to any of the required concomitant drugs or supportive treatments.

19. Patients unwilling or unable to comply with the protocol.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• Selinexor
Selinexor will be given as an oral dose 40 mg (2 20 mg tablets) QW on Days 1, 8, 15, and 22 of each 28-day cycle.
• Elotuzumab
Elotuzumab will be given IV 10 mg/kg on Days 1, 8, 15, and 22 of cycle 1 and 2 then 20 mg/kg on Day 1 of cycles =3 of each 28-day cycle.
• Pomalidomide
Pomalidomide will be given as an oral 4 mg dose QD on Days 1 to 21 of each 28-day cycle.
• Dexamethasone Oral
Dexamethasone will be given as an oral 40 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Preferred dosing of dexamethasone is 40 mg QW for patients who are =75 years of age (20 mg QW for >75-year-old patients at the Investigator's discretion) before QW dosing of selinexor, however, it may be divided over 2 days at the Investigator's discretion.

Locations

Country	Name	City	State
France	CHRU Hôpital Claude Huriez	Lille
France	CHRU Hôtel Dieu	Nantes
France	CHU Hôpital Saint Antoine	Paris
France	La Pitié	Paris
France	Paris Necker	Paris
France	CHU Poitiers - Pôle régional de Cancérologie	Poitiers
France	Pôle IUCT Oncopole CHU	Toulouse
Germany	Universitätsklinikum Hamburg - Eppendorf	Hamburg
Germany	University Hospital of Heidelberg	Heidelberg
Germany	University Hospital of Cologne	Köln
Germany	University Hospital of Münster	Münster
Germany	University Hospital of Würzburg	Würzburg
Greece	Alexandra General Hospital -Department of Clinical Therapeutics N.K. Univ. of Athens	Athens
Greece	General Hospital of Athens"Evangelismos"	Athens
Greece	St Savvas Cancer Hospital	Athens
Greece	University General Hospital of Patras	Patras
Greece	Theagenion Cancer Hospital	Thessaloníki
Italy	Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi Di Ancona	Ancona
Italy	A.O. Papa Giovanni XXIII	Bergamo
Italy	Bologna	Bologna
Italy	ASST Spedali Civili di Brescia - Ematologia	Brescia
Italy	Brescia	Brescia
Italy	Ospedale Oncologico 'A. Businco'	Cagliari
Italy	Az.Osp. Di Careggi_Dh ematologia	Firenze
Italy	A.O.U. Policlinico S. Martino - Ematologia	Genova
Italy	Hospital IRST	Meldola
Italy	A.O.U. Policlinico 'G. Martino'	Messina
Italy	A.O.U. Maggiore della Carità di Novara	Novara
Italy	Ospedale S. Eugenio	Roma
Italy	A.O. S. Maria	Terni
Italy	A.O.U. Città della Salute e della Scienza di Torino - SC Ematologia U	Torino
Italy	Azienda Ospedaliera Universitaria di Udine	Udine
Netherlands	Amphia ziekenhuis	Breda
Netherlands	Erasmus MC	Rotterdam
Spain	Hospital Clinic I Provincial de Barcelona	Barcelona
Spain	Institut Catala D Oncolocia Hospitalet - Hospital Duran i Reynals	Barcelona
Spain	Hospital Universitario 12 de Octubre	Madrid
Spain	H. General Universitario Morales Meseguer	Murcia
Spain	Clínica Universidad de Navarra (CUN)	Pamplona
Spain	Hospital Universitario de Salamanca	Salamanca
Spain	H. Universitario Marqués de Valdecilla	Santander
Spain	Complejo Hospitalario Universitario de Santiago (CHUS)	Santiago De Compostela
Spain	H.U. La Fe	Valencia
United States	Hematology Oncology Clinic	Baton Rouge	Louisiana
United States	American Oncology Partners of Maryland	Bethesda	Maryland
United States	MD Anderson Cancer Center at Cooper	Camden	New Jersey
United States	Medical University of South Carolina. Hollings Cancer Center	Charleston	South Carolina
United States	UCHealth Cancer Center - Harmony Campus	Fort Collins	Colorado
United States	Florida Cancer Specialists South	Fort Myers	Florida
United States	University of California, San Francisco	Fresno	California
United States	East Carolina University	Greenville	North Carolina
United States	Ascension St. John Hospital	Grosse Pointe Woods	Michigan
United States	Hawaii Cancer Care	Honolulu	Hawaii
United States	Kaiser Permanente Southern California	Irvine	California
United States	Nebraska Hematology - Oncology, P.C.	Lincoln	Nebraska
United States	Los Angeles Hematology Oncology Medical Group	Los Angeles	California
United States	Cancer Care Specialists	Reno	Nevada
United States	Florida Cancer Specialists North	Saint Petersburg	Florida
United States	June E. Nylen Cancer Center	Sioux City	Iowa
United States	Gibbs Cancer Center	Spartanburg	South Carolina
United States	Florida Cancer Specialists Panhandle	Tallahassee	Florida
United States	Renovatio Clinical Research	The Woodlands	Texas
United States	The University of Arizona Cancer Center	Tucson	Arizona
United States	Berenson Oncology	West Hollywood	California
United States	Florida Cancer Specialists East	West Palm Beach	Florida
United States	Reading Hospital - McGlinn Cancer Institute	West Reading	Pennsylvania
United States	The Oncology Institute of Hope and Innovation	Whittier	California
United States	Novant Health Cancer Institute	Winston-Salem	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
European Myeloma Network	Karyopharm Therapeutics Inc

Countries where clinical trial is conducted

United States,  France,  Germany,  Greece,  Italy,  Netherlands,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival (PFS)	from date of randomization until the date of first confirmed progressive disease (PD), per IMWG response criteria, or death due to any cause, whichever occurs first.	from randomization to the date of disease progression or death (approximately up to 5 years)
Secondary	Overall Response Rate (ORR)	defined as any response =PR (i.e., PR [partial response], VGPR [very good partial response], CR ([complete response], or sCR [stringent complete response])	from screening until end of treatment/progressive disease (approximately up to 2 years)
Secondary	Overall survival (OS)	Overall Survival	From randomization until death from any cause (up to 3 years after end of treatment)
Secondary	Duration of response	Duration of response (PR or better), duration of CR, duration of sCR, and duration of minimal residual disease (MRD) -negative status, are calculated from the date of the initial documentation of a response (PR or better), or CR or better, or sCR, or MRD-negative status to the date of the first documented evidence of disease progression, as defined in the IMWG criteria, whichever occurs first.	screening, Day 1 of each treatment cycle (each cycle is 28 days), at end of treatment, and every 3 months up to 3 years
Secondary	Time to response	Time to response (PR or better), time to CR/sCR are defined as the time from randomization to date of initial response (or initial CR/sCR)	screening, Day 1 of each treatment cycle (each cycle is 28 days), at end of treatment, and every 3 months up to 3 years
Secondary	Progression-free survival on the next line of therapy (PFS2)	Progression-free survival on the next line of therapy (PFS2) is defined as the time from randomization to progression on the next line of treatment or death, whichever comes first.	the time from randomization to progression on the next line of treatment or death, whichever comes first., assessed up to approx. 5 years
Secondary	Change in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core module (EORTC QLQ-C30) score and the difference between-treatment arms	The EORTC QLQ-C30 is a 30-item questionnaire containing both single and multi-item measures. These include five functional scales (Physical, Role, Cognitive, Emotional, and Social Functioning), three symptom scales (Fatigue, Pain, and Nausea/Vomiting), a Global Health Status/ Quality-of-Life (QoL) scale, and six single items (Constipation, Diarrhea, Insomnia, Dyspnea, Appetite Loss, and Financial Difficulties). The scores ranges from 0-100, a high score for functional scales and for Global Health Status/QoL represent better functioning ability or Health-Related Quality-of-Life (HRQoL), whereas a high score for symptom scales and single items represents significant symptomatology.	screening, Day 1 of each treatment cycle (each cycle is 28 days), at end of treatment (up to 2 years)
Secondary	Change in EORTC QLQ- 20-item Multiple Myeloma module (MY-20) score and the difference between-treatment arms	The EORTC QLQ-MY20 is a supplement to the QLQ-C30 instrument used in subjects with MY. The module comprises 20 questions that address four myeloma-specific HRQoL domains: Disease Symptoms, Side Effects of Treatment, Future Perspective, and Body Image. A high score for Disease Symptoms and Side Effects of Treatment represents a high level of symptomatology or problems, whereas a high score for Future Perspective and Body Image represents better outcomes.	screening, Day 1 of each treatment cycle (each cycle is 28 days), at end of treatment (approximately up to 2 years)
Secondary	EQ-5D-5L health utility values and the difference between-treatment arms	The EQ-5D-5L is a 5 item questionnaire that assesses 5 domains including mobility, self care, usual activities, pain/discomfort, and anxiety/depression plus a visual analog scale rating "health today"	screening, Day 1 of each treatment cycle (each cycle is 28 days), at end of treatment (approximately up to 2 years)
Secondary	safety and tolerability of SPd versus EloPd in patients with RRMM	Safety and tolerability of study treatment will be evaluated based on occurrence, nature and severity of adverse events as categorized by the Common Terminology Criteria of Adverse Events (CTCAE) v5.0	continuously from screening untill 30 days after last study treatment. (approximately up to 2 years)